-
1.
公开(公告)号:US20100189651A1
公开(公告)日:2010-07-29
申请号:US12686344
申请日:2010-01-12
申请人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Frederick Gluck , Jason Sagert , Patrick Daugherty
发明人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Frederick Gluck , Jason Sagert , Patrick Daugherty
IPC分类号: A61K49/00 , C07K1/107 , C07K16/00 , A61K39/395 , A61P35/00
CPC分类号: C07K16/22 , A61K39/3955 , A61K47/6845 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K7/06 , C07K7/08 , C07K14/001 , C07K16/00 , C07K16/18 , C07K16/241 , C07K16/28 , C07K16/2818 , C07K16/2845 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2896 , C07K16/30 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C07K2319/50 , G01N33/6845 , G01N33/6854
摘要: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
摘要翻译: 本公开提供了修饰的抗体,其含有用掩蔽部分(MM)修饰的抗体或抗体片段(AB)。 这样的修饰抗体可以进一步与可切割部分(CM)偶联,产生可激活抗体(AAs),其中CM能够被切割,还原,光解或以其它方式修饰。 AAs可以表现出可激活的构象,使得AB在例如通过在能够切割,还原或光解所述蛋白质的试剂存在下,通过CM的切割,还原或光解去除MM来更容易地进行靶标 厘米。 本公开进一步提供了制备和使用这些修饰抗体和可激活抗体的方法。
-
公开(公告)号:US08513390B2
公开(公告)日:2013-08-20
申请号:US13455924
申请日:2012-04-25
申请人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Fred Gluck , Jason Sagert , Patrick Daugherty
发明人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Fred Gluck , Jason Sagert , Patrick Daugherty
CPC分类号: C07K16/22 , A61K39/3955 , A61K47/6845 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K7/06 , C07K7/08 , C07K14/001 , C07K16/00 , C07K16/18 , C07K16/241 , C07K16/28 , C07K16/2818 , C07K16/2845 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2896 , C07K16/30 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C07K2319/50 , G01N33/6845 , G01N33/6854
摘要: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
-
3.
公开(公告)号:US20120207756A1
公开(公告)日:2012-08-16
申请号:US13455924
申请日:2012-04-25
申请人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Frederick W. Gluck , Jason Sagert , Patrick Daugherty
发明人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Frederick W. Gluck , Jason Sagert , Patrick Daugherty
IPC分类号: A61K39/395 , A61P35/00 , A61P9/00 , C07K1/107 , C12N15/63 , C12P21/00 , C12P21/02 , C12N15/62 , C07K19/00
CPC分类号: C07K16/22 , A61K39/3955 , A61K47/6845 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K7/06 , C07K7/08 , C07K14/001 , C07K16/00 , C07K16/18 , C07K16/241 , C07K16/28 , C07K16/2818 , C07K16/2845 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2896 , C07K16/30 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C07K2319/50 , G01N33/6845 , G01N33/6854
摘要: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
摘要翻译: 本公开提供了修饰的抗体,其含有用掩蔽部分(MM)修饰的抗体或抗体片段(AB)。 这样的修饰抗体可以进一步与可切割部分(CM)偶联,产生可激活抗体(AAs),其中CM能够被切割,还原,光解或以其它方式修饰。 AAs可以表现出可激活的构象,使得AB在例如通过在能够切割,还原或光解所述蛋白质的试剂存在下,通过CM的切割,还原或光解来除去MM来更容易地进行靶标 厘米。 本公开进一步提供了制备和使用这些修饰抗体和可激活抗体的方法。
-
4.
公开(公告)号:US08563269B2
公开(公告)日:2013-10-22
申请号:US13315623
申请日:2011-12-09
申请人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Frederick W. Gluck , Jason Sagert , Patrick Daugherty
发明人: Nancy E. Stagliano , James W. West , Kathryn Kamath , Paul H. Bessette , Frederick W. Gluck , Jason Sagert , Patrick Daugherty
IPC分类号: C12P21/08 , C12N15/74 , C12N9/00 , C12N15/62 , C07H21/04 , C07K16/28 , C07K16/46 , C07K14/00
CPC分类号: C07K16/22 , A61K39/3955 , A61K47/6845 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K7/06 , C07K7/08 , C07K14/001 , C07K16/00 , C07K16/18 , C07K16/241 , C07K16/28 , C07K16/2818 , C07K16/2845 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2896 , C07K16/30 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/40 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C07K2319/50 , G01N33/6845 , G01N33/6854
摘要: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
摘要翻译: 本公开提供了修饰的抗体,其含有用掩蔽部分(MM)修饰的抗体或抗体片段(AB)。 这样的修饰抗体可以进一步与可切割部分(CM)偶联,产生可激活抗体(AAs),其中CM能够被切割,还原,光解或以其它方式修饰。 AAs可以表现出可激活的构象,使得AB在例如通过在能够切割,还原或光解所述蛋白质的试剂存在下,通过CM的切割,还原或光解来除去MM来更容易地进行靶标 厘米。 本公开进一步提供了制备和使用这些修饰抗体和可激活抗体的方法。
-
公开(公告)号:US08399219B2
公开(公告)日:2013-03-19
申请号:US12711199
申请日:2010-02-23
CPC分类号: C07K14/56 , A61K38/00 , A61K47/64 , A61K47/65 , C07K14/00 , C07K14/555 , C07K14/565 , C07K14/57 , C07K14/705 , C07K16/00 , C07K19/00 , C07K2319/10 , C07K2319/31 , C07K2319/33 , C07K2319/50 , C07K2319/70 , C07K2319/90 , C12N15/1037 , G01N33/6866
摘要: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.
摘要翻译: 本公开内容提供了蛋白质和可激活的前蛋白组合物。 前蛋白含有功能蛋白(即其全长蛋白质或其功能片段),其与抑制功能蛋白与其靶标或结合配偶体的结合的肽掩模偶联。 可激活的蛋白质包含与肽掩模偶联的功能性蛋白质,并进一步与可活化接头偶联,其中在非活化状态下,肽掩模抑制功能性蛋白质与其靶标或结合配偶体的结合,并且在活化状态下 肽掩模不抑制功能蛋白与其靶或结合配偶体的结合。 前体蛋白可以提供如果不抑制结合其结合配偶体的功能性蛋白质在非处理部位的结合,则可以提供降低的毒性和不良副作用。 前体蛋白可进一步提供改善的生物分布特征。 含有肽掩模的前体蛋白可以显示比不含肽掩模的相应功能蛋白质更长的体内或血清半衰期。 本公开进一步提供筛选,制备和使用这些蛋白质的方法。
-
公开(公告)号:US20100221212A1
公开(公告)日:2010-09-02
申请号:US12711199
申请日:2010-02-23
IPC分类号: A61K38/21 , C07K14/00 , C07K14/555 , C07K16/00 , A61K38/16 , A61K39/395 , A61P35/04
CPC分类号: C07K14/56 , A61K38/00 , A61K47/64 , A61K47/65 , C07K14/00 , C07K14/555 , C07K14/565 , C07K14/57 , C07K14/705 , C07K16/00 , C07K19/00 , C07K2319/10 , C07K2319/31 , C07K2319/33 , C07K2319/50 , C07K2319/70 , C07K2319/90 , C12N15/1037 , G01N33/6866
摘要: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.
摘要翻译: 本公开内容提供了蛋白质和可激活的前蛋白组合物。 前蛋白含有功能蛋白(即其全长蛋白质或其功能片段),其与抑制功能蛋白与其靶标或结合配偶体的结合的肽掩模偶联。 可激活的蛋白质包含与肽掩模偶联的功能性蛋白质,并进一步与可活化接头偶联,其中在非活化状态下,肽掩模抑制功能性蛋白质与其靶标或结合配偶体的结合,并且在活化状态下 肽掩模不抑制功能蛋白与其靶或结合配偶体的结合。 前体蛋白可以提供如果不抑制结合其结合配偶体的功能性蛋白质在非处理部位的结合,则可以提供降低的毒性和不良副作用。 前体蛋白可进一步提供改善的生物分布特征。 含有肽掩模的前体蛋白可以显示比不含肽掩模的相应功能蛋白质更长的体内或血清半衰期。 本公开进一步提供筛选,制备和使用这些蛋白质的方法。
-
-
-
-
-